insights_auto
Hvorfor har DRREDDY gått ned? 2,51%?
Gå mer i dybdenchevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 202,00 INR
arrow_downward
−2,51%(−31,00) 1 D
1. okt., 15:30:00 GMT+5:30 · INR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for DRREDDY …
Åpne
1 233,00 INR
Høy
1 233,90 INR
Lav
1 194,90 INR
Markedsverdi
1,00 bill.
Snittvolum
1,67 mill.
Volum
2,61 mill.
Utbytte
0,67 %
Kvartalsvis utbytte
2,00 INR
Første dato etter utbytte
10. juli 2026
P/E-forhold
31,08
52 u høy
1 414,90 INR
52 u lav
1 101,00 INR
EPS
38,67 INR
Utestående aksjer
166,06 mill.
Antall ansatte
28k
Åpne
1 233,00 INR
Høy
1 233,90 INR
Lav
1 194,90 INR
Markedsverdi
1,00 bill.
Snittvolum
1,67 mill.
Volum
2,61 mill.
Utbytte
0,67 %
Kvartalsvis utbytte
2,00 INR
Første dato etter utbytte
10. juli 2026
P/E-forhold
31,08
52 u høy
1 414,90 INR
52 u lav
1 101,00 INR
EPS
38,67 INR
Utestående aksjer
166,06 mill.
Antall ansatte
28k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Invezz
·
for 1 døgn siden
Dow stiger 260 poeng etter svake jobbtall som løfter USAs aksjer
Invezz
·
for 2 døgn siden
Dow-futures klatrer 300 poeng: 5 ting å vite før Wall Street åpner
Invezz
·
for 2 døgn siden
Dow stiger etter at amerikanske aksjer hentet seg da statsrenter nådde 24-års-topp
Invezz
·
for 2 døgn siden
Dow stiger 324 poeng etter svake jobbtall som demper odds for renteheving i oktober
Profil
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Om Dr Reddy's Laboratories Ltd
Administrerende direktørErez Israeli
Ansatte27,5k
Grunnlagt1984
HovedkontorHyderabad, Andhra Pradesh, India
Sektor-
Nettsteddrreddys.com